Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Substance use disorders following cancer diagnosis in adolescents and young adults: A Canadian population-based study.

Sapna Oberoi, Allan Garland, Pascal Lambert et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23102

e23102 Background: Substance use disorders (SUDs) can adversely affect cancer treatment and survivorship outcomes, includi...

Beyond geography: The intersecting impact of rurality, race, and depression on breast cancer survival.

Ilias Jerrar, Fnu Karishma, Mohammad Hatamleh et al. Jun 01, 2026 pp. 11137-11137 10.1200/jco.2026.44.16_suppl.11137

11137 Background: Rural–urban disparities in breast cancer outcomes are well-documented, with rural populations typically...

National mortality trends of malignant melanoma associated with cerebrovascular diseases in the United States (1999-2023).

Ismail Mazhar, Elangovan Krishnan, Sophia Ahmed et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21518

e21518 Background: Malignant melanoma and cerebrovascular diseases (CVDs) pose major U.S. public health burdens, with mela...

Optimal timing of circulating tumor DNA (ctDNA) dynamics to prognosticate immune checkpoint inhibitors (ICI) efficacy in patients with advanced stage melanoma.

Vincent T. Ma, Amir W. Forati, Alice Yao Zhou et al. Jun 01, 2026 pp. 9534-9534 10.1200/jco.2026.44.16_suppl.9534

9534 Background: ctDNA predicts relapse in resected tumors, but its role in advanced disease is less defined. We previousl...

Prognostic biomarkers in retroperitoneal dedifferentiated liposarcoma and their clinical impact on patient management.

Ilaria Tortorelli, Elena Bellan, Marta Sbaraglia et al. Jun 01, 2026 pp. 11546-11546 10.1200/jco.2026.44.16_suppl.11546

11546 Background: The prognosis of patients (pts) with retroperitoneal dedifferentiated liposarcoma (DDLPS) is mainly driv...

Family cancer history and perceived value of multi-cancer early detection tests in a national U.S. sample.

Chinenye Egwuonwu, Onyema Chido-Amajuoyi, Chinenye M. Okafor et al. Jun 01, 2026 pp. 10519-10519 10.1200/jco.2026.44.16_suppl.10519

10519 Background: Family history of cancer has a strong influence on individuals’ perceived cancer risk and has been shown...

Genotype–anatomic correlates and survival outcomes in a molecularly validated 90-patient cohort of skeletal and extraskeletal Ewing sarcomas and mimics.

Abdulaziz AlJassim, Rola Ali, Muath A.M.A.H Alnassar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23501

e23501 Background: Ewing sarcoma (ES)—defined by FET::ETS rearrangements—and Ewing-like small round-cell mimics represent...

Trends in gastric cancer-related mortality across world bank income groups, 1980–2023: A retrospective analysis.

Sanhia Maheshwari, Minahil Zahid, Sarim Hassan Shahab et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16043

e16043 Background: Gastric cancer is a major global health concern and a leading cause of cancer-related mortality worldwi...

Adjuvant donafenib plus anti–PD-1 therapy in hepatocellular carcinoma with high-risk features after curative resection: A real-world study.

Chenggang Li, Hanchuan Shen, Yang Liu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16254

e16254 Background: Patients with hepatocellular carcinoma (HCC) and high-risk pathological features have a substantial ris...

Trends and factors associated with glucagon-like peptide 1 receptor agonists prescription for cancer populations with type 2 diabetes.

Ilana Graetz, Changchuan Jiang, Xuesong Han et al. Jun 01, 2026 pp. 11181-11181 10.1200/jco.2026.44.16_suppl.11181

11181 Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in cancer survivors with Type...

A phase 1/2 study of mRNA-2808 in participants with relapsed or refractory multiple myeloma.

Hans C. Lee, Luciano J. Costa, Binod Dhakal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps7580

TPS7580 Background: Multiple myeloma (MM) remains mostly incurable despite therapeutic advances and relapsed or refractory...

Treatment patterns and outcomes in pacritinib-treated patients with MF and higher platelet count: MY-PAC study.

Douglas Tremblay, Abiola Oladapo, Michael Marrone et al. Jun 01, 2026 pp. 6575-6575 10.1200/jco.2026.44.16_suppl.6575

6575 Background: Pacritinib (PAC), a JAK1-sparing JAK2/IRAK1/ACVR1 inhibitor has shown spleen volume and symptom improveme...

Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL).

Daniel Arthur Ermann, Deborah M. Stephens, Xiaoliang Wang et al. Jun 01, 2026 pp. 7047-7047 10.1200/jco.2026.44.16_suppl.7047

7047 Background: Covalent BTKi monotherapies are standard of care for 1L CLL in the US. However, there is a lack of head-t...

GLP-1 receptor agonist utilization and survival outcomes in a large U.S. community oncology cohort.

Ila Sruti, Chuck Wentworth, Ari D. Marcus et al. Jun 01, 2026 pp. 11017-11017 10.1200/jco.2026.44.16_suppl.11017

11017 Background: GLP1 use has increased with 12.4% of U.S. adults reported using these treatments, driven in part by the...

Large cell carcinoma with rhabdoid phenotype: Demographics, treatment, and survival in the NCDB.

Anaum Showkat, Michael Martin, Amber Chang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20078

e20078 Background: Large cell carcinoma with rhabdoid phenotype (LCC-RP) constitutes <1% of lung malignancies and is as...

Phase 2 trial of lisocabtagene maraleucel for minimal residual disease in patients with large B-cell lymphoma.

Dai Chihara, Ruitao Lin, Alexander Boardman et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps7107

TPS7107 Background: Patients with relapsed/refractory large B-cell lymphoma (LBCL) have a poor prognosis. Identifying pati...

Impact of rurality on screening and prevention strategies for patients with hereditary breast and ovarian cancer syndrome.

Charles Jakubik, Rex Jewell, Wendy McKinnon et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22662

e22662 Background: Patients with hereditary breast and ovarian cancer syndrome (HBOC) with a germline pathogenic variant i...

Mapping the treatment journey following antibody-drug conjugate (ADC) initiation: Sequencing patterns and real world overall survival (rwOS) in non-breast solid tumors in a US community setting.

Changxia Shao, Alisha Monnette Kimble, Juliet Ndukum et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23362

e23362 Background: With the clinical application of ADCs in solid tumors, there is a need to understand treatment sequenci...

Interim results from a prospective phase II study of stratified treatment of localized cervical esophageal squamous cell carcinoma by induction immunochemotherapy (SCENIC trial).

Chunguang Li, Jun Liu, Ming Zhang et al. Jun 01, 2026 pp. 4086-4086 10.1200/jco.2026.44.16_suppl.4086

4086 Background: Definitive concurrent chemoradiotherapy (dCRT) is the standard treatment for cervical esophageal squamous...

Clinical outcomes and safety profile of dendritic cell–based vaccination in melanoma: Meta-analysis of reconstructed time to event data.

Jean H. Maselli Schoueri, Isabella Romagnoli Buonopane, Lucas Diniz da Conceição et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14597

e14597 Background: Dendritic cell (DC) vaccination has been investigated as adjuvant immunotherapy for melanoma; however,...

Reducing stress and improving quality of life for adult breast cancer patients.

Danna Remen, Amy H. Comander Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23428

e23428 Background: Ellie Fund provides essential non-medical support services to ease daily life stressors for individuals...

Neighborhood social vulnerability and chemotherapy response in breast cancer patients.

Taylor Landry, Sujata Ojha, William Steele Sessions et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23083

e23083 Background: Sociodemographic disparities are a well-known influence on oncologic outcomes, however their relationsh...

Comparative effectiveness of doublet versus triplet therapy in high-volume metastatic hormone-sensitive prostate cancer: A real-world evidence study.

Olesia Stativko, Ilya Pokataev, Alexey Rumyantsev et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17084

e17084 Background: Although the combination of androgen deprivation therapy (ADT) with an androgen receptor pathway inhibi...

National trends in non-Hodgkin lymphoma incidence in the CAR-T era: A population-based analysis using SEER Explorer data.

Reshman Naga Kumar Jonnadula, Sai Lahari Sangaraju, Siri Sanmayi Medicherla et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19062

e19062 Background: Non-Hodgkin lymphoma (NHL) is a common hematologic malignancy in the United States. Chimeric antigen re...

Predictors of progression, survival, and psychosocial burden in early-stage breast cancer: A real-world cohort study.

Ali Sanjari Moghaddam, Jake Fanizza, Kit Yu Lu Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12761

e12761 Background: While early-stage breast cancer is associated with high survival rates, recurrence risk and long-term p...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page